$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2021 Q4 Form 10-Q Financial Statement

#000129913021000216 Filed on November 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $36.02M $34.89M $19.08M
YoY Change 32.72% 82.83% -12.93%
Cost Of Revenue $19.25M $19.52M $12.02M
YoY Change 22.32% 62.45% -19.89%
Gross Profit $16.77M $15.36M $7.064M
YoY Change 47.07% 117.5% 2.17%
Gross Profit Margin 46.55% 44.04% 37.02%
Selling, General & Admin $37.32M $31.61M $14.77M
YoY Change 107.91% 113.96% -26.38%
% of Gross Profit 222.59% 205.71% 209.12%
Research & Development $42.58M $27.51M $16.47M
YoY Change 144.27% 67.05% 10.06%
% of Gross Profit 253.94% 179.04% 233.11%
Depreciation & Amortization $2.483M $1.899M $1.580M
YoY Change 55.19% 20.19% -16.4%
% of Gross Profit 14.81% 12.36% 22.37%
Operating Expenses $81.04M $89.84M $31.24M
YoY Change 129.12% 187.59% -10.82%
Operating Profit -$64.27M -$74.48M -$24.18M
YoY Change 168.14% 208.07% -14.01%
Interest Expense -$3.479M $3.673M $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $1.000K -$133.0K $467.0K
YoY Change -100.0% -128.48% -235.36%
Pretax Income -$68.15M -$78.28M -$23.71M
YoY Change -190.94% 230.19% -18.59%
Income Tax $1.175M -$94.82M
% Of Pretax Income
Net Earnings -$69.33M $16.54M -$23.71M
YoY Change -192.51% -169.77% -18.59%
Net Earnings / Revenue -192.48% 47.42% -124.24%
Basic Earnings Per Share $0.08 -$0.14
Diluted Earnings Per Share -$313.8K $0.08 -$0.14
COMMON SHARES
Basic Shares Outstanding 220.6M 202.2M 166.9M
Diluted Shares Outstanding 215.1M 166.9M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.056B $830.4M $221.9M
YoY Change 213.46% 274.24% 247.88%
Cash & Equivalents $460.7M $425.4M $69.03M
Short-Term Investments $595.1M $405.0M $152.9M
Other Short-Term Assets $7.894M $7.693M $3.200M
YoY Change 38.49% 140.41% 18.52%
Inventory $24.60M $18.28M $15.94M
Prepaid Expenses
Receivables $24.24M $23.95M $11.81M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.101B $1.130B $239.5M
YoY Change 209.67% 371.72% 211.29%
LONG-TERM ASSETS
Property, Plant & Equipment $32.50M $31.12M $26.57M
YoY Change 30.54% 17.13% -15.97%
Goodwill $410.0M $411.5M
YoY Change
Intangibles $411.0M $411.2M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.170M $70.00K $42.00K
YoY Change 2620.93% 66.67% 2.44%
Total Long-Term Assets $905.8M $904.4M $60.81M
YoY Change 1451.27% 1387.17% -12.08%
TOTAL ASSETS
Total Short-Term Assets $1.101B $1.130B $239.5M
Total Long-Term Assets $905.8M $904.4M $60.81M
Total Assets $2.007B $2.034B $300.3M
YoY Change 384.8% 577.33% 105.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.00M $4.960M $5.406M
YoY Change 207.4% -8.25% -33.35%
Accrued Expenses $36.26M $30.82M $15.08M
YoY Change 109.0% 104.39% -4.7%
Deferred Revenue $10.98M $9.773M $6.982M
YoY Change 25.85% 39.97% 9.45%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $71.71M $55.61M $130.3M
YoY Change 86.25% -57.31% 156.97%
LONG-TERM LIABILITIES
Long-Term Debt $896.1M $895.9M $0.00
YoY Change
Other Long-Term Liabilities $3.471M $4.850M $40.60M
YoY Change 361.57% -88.05% -8.56%
Total Long-Term Liabilities $3.471M $4.850M $40.60M
YoY Change 361.57% -88.05% -8.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.71M $55.61M $130.3M
Total Long-Term Liabilities $3.471M $4.850M $40.60M
Total Liabilities $1.216B $1.193B $170.8M
YoY Change 1449.24% 598.59% 79.63%
SHAREHOLDERS EQUITY
Retained Earnings -$1.218B -$1.149B -$1.112B
YoY Change 17.48% 3.32% 4.28%
Common Stock $221.0K $221.0K $180.0K
YoY Change 15.1% 22.78% 17.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $791.0M $840.8M $129.5M
YoY Change
Total Liabilities & Shareholders Equity $2.007B $2.034B $300.3M
YoY Change 384.8% 577.33% 105.54%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$69.33M $16.54M -$23.71M
YoY Change -192.51% -169.77% -18.59%
Depreciation, Depletion And Amortization $2.483M $1.899M $1.580M
YoY Change 55.19% 20.19% -16.4%
Cash From Operating Activities -$31.71M -$40.66M -$17.80M
YoY Change 122.2% 128.4% 3.13%
INVESTING ACTIVITIES
Capital Expenditures -$2.842M -$1.119M -$530.0K
YoY Change 3960.0% 111.13% -36.14%
Acquisitions
YoY Change
Other Investing Activities $68.60M -$290.5M -$63.11M
YoY Change -169.7% 360.35% -408.0%
Cash From Investing Activities $65.75M -$291.6M -$63.64M
YoY Change -166.76% 358.27% -423.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.324M 299.7M 107.1M
YoY Change -98.95% 179.71% 32363.64%
NET CHANGE
Cash From Operating Activities -31.71M -40.66M -17.80M
Cash From Investing Activities 65.75M -291.6M -63.64M
Cash From Financing Activities 1.324M 299.7M 107.1M
Net Change In Cash 35.37M -32.65M 25.69M
YoY Change 169.58% -227.08% 841.03%
FREE CASH FLOW
Cash From Operating Activities -$31.71M -$40.66M -$17.80M
Capital Expenditures -$2.842M -$1.119M -$530.0K
Free Cash Flow -$28.87M -$39.54M -$17.27M
YoY Change 103.28% 128.93% 5.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001299130
CY2020Q4 pacb Contract Termination
ContractTermination
CY2021Q3 pacb Contract Termination
ContractTermination
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Registrant Name
EntityRegistrantName
Pacific Biosciences of California, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
16-1590339
dei Entity Address Address Line1
EntityAddressAddressLine1
1305 O’Brien Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
521-8000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
220598363
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
425388000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81611000
dei Trading Symbol
TradingSymbol
PACB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
654502000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
237203000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23946000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16837000
CY2021Q3 us-gaap Inventory Net
InventoryNet
18276000
CY2020Q4 us-gaap Inventory Net
InventoryNet
14230000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7193000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4870000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
500000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
836000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1129805000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
355587000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31119000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24899000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45862000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29951000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4560000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3500000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
411206000
CY2021Q3 us-gaap Goodwill
Goodwill
411533000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43000
CY2021Q3 us-gaap Assets
Assets
2034155000
CY2020Q4 us-gaap Assets
Assets
413980000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4960000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3579000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30820000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17350000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9773000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8722000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7128000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4332000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2927000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4519000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
55608000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38502000
CY2021Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
123000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
123000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19523000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18447000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1568000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
168574000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49954000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37667000
CY2021Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
895915000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4850000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
752000
CY2021Q3 us-gaap Liabilities
Liabilities
1193348000
CY2020Q4 us-gaap Liabilities
Liabilities
78489000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
220547000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
220547000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
192294000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
192294000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
221000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
192000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1989322000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1372083000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
85000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1148763000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1036869000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
840807000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
335491000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2034155000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
413980000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
34887000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19082000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
94494000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
51757000
CY2021Q3 us-gaap Gross Profit
GrossProfit
15364000
CY2020Q3 us-gaap Gross Profit
GrossProfit
7064000
us-gaap Gross Profit
GrossProfit
42094000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12018000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
52400000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30592000
us-gaap Gross Profit
GrossProfit
21165000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27508000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16467000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70323000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46727000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31606000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14772000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
86804000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54846000
CY2021Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
30726000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
30726000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
89840000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
31239000
us-gaap Operating Expenses
OperatingExpenses
187853000
us-gaap Operating Expenses
OperatingExpenses
101573000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-74476000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24175000
us-gaap Operating Income Loss
OperatingIncomeLoss
-145759000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80408000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-52000000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
34000000
CY2021Q3 us-gaap Interest Expense
InterestExpense
3673000
us-gaap Interest Expense
InterestExpense
9051000
us-gaap Interest Expense
InterestExpense
267000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
467000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1143000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-78282000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23708000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-206718000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-45532000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-94824000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-94824000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
16542000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23708000
us-gaap Net Income Loss
NetIncomeLoss
-111894000
us-gaap Net Income Loss
NetIncomeLoss
-45532000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-125000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-58000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
113000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16575000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23833000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111952000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45419000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
202194000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166862000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
198545000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158195000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215127000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166862000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
198545000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158195000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
258245000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
16542000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4811000
CY2021Q3 pacb Stock Issued During Period In Private Placement Net Of Issuance Costs
StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts
294845000
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
237884000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28447000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
840807000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
41392000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23708000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-125000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13347000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93598000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4992000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
129496000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
335491000
us-gaap Net Income Loss
NetIncomeLoss
-111894000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-58000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
30122000
pacb Stock Issued During Period In Private Placement Net Of Issuance Costs
StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts
294845000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
237884000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54417000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
840807000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54917000
us-gaap Net Income Loss
NetIncomeLoss
-45532000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
113000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14174000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12258000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
129496000
us-gaap Net Income Loss
NetIncomeLoss
-111894000
us-gaap Net Income Loss
NetIncomeLoss
-45532000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-52000000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
34000000
us-gaap Depreciation
Depreciation
4943000
us-gaap Depreciation
Depreciation
4827000
pacb Amortization Of Intangible Assets And Research Development Expense
AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense
154000
pacb Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
2403000
pacb Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
2127000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
381000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
129000
us-gaap Share Based Compensation
ShareBasedCompensation
54417000
us-gaap Share Based Compensation
ShareBasedCompensation
12258000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-3107000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
141000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-94824000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6871000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3428000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5453000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2988000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-216000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2955000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10267000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1646000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-17930000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
818000
us-gaap Operating Lease Payments
OperatingLeasePayments
3231000
us-gaap Operating Lease Payments
OperatingLeasePayments
2791000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2996000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
360000
pacb Increase Decrease In Deferred Gain From Reverse Termination Fee
IncreaseDecreaseInDeferredGainFromReverseTerminationFee
98000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79472000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
33766000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3089000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
972000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
857421000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
234555000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
212734000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
223285000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
114700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-744284000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-120827000
pacb Proceeds From Repayments Of Contract Termination
ProceedsFromRepaymentsOfContractTermination
-52000000
pacb Proceeds From Repayments Of Contract Termination
ProceedsFromRepaymentsOfContractTermination
34000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
16000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
895536000
pacb Proceeds From Issuance Of Common Stock Under Equity Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts
294846000
pacb Proceeds From Issuance Of Common Stock Under Equity Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts
93788000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30121000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14174000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-246000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1168257000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125962000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
344501000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
38901000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85947000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33627000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
430448000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72528000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
425388000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69028000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5060000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
430448000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72528000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
237884000
CY2021Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
34887000
CY2020Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
19082000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
94494000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
51757000
CY2021Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-54802000
CY2020Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-38473000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-213715000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-42892000
CY2021Q3 pacb Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.25
CY2020Q3 pacb Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.21
pacb Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.97
pacb Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.24
pacb Income Tax Benefit From Reduction In Deferred Tax Assets Valuation Allowance
IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance
94800000
pacb Merger Termination
MergerTermination
NOTE 4. TERMINATION OF MERGER WITH ILLUMINA On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the “Illumina Merger Agreement”) with Illumina, Inc. (“Illumina”) and FC Ops Corp., a wholly owned subsidiary of Illumina (“Illumina Merger Sub”). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the “Termination Agreement”). Continuation Advances from IlluminaAs part of the Termination Agreement, Illumina paid us cash payments (“Continuation Advances”) of $18.0 million during the fourth quarter of 2019 and $34.0 million during the first quarter of 2020. We recorded the $34.0 million as part of other income in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the nine months ended September 30, 2020. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028, $52.0 million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded as other expense in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the nine months ended September 30, 2021. Please refer to Note 5. Summary of Significant Accounting Policies for the accounting treatment of the Continuation Advances.Reverse Termination Fee from IlluminaAs part of the Termination Agreement, Illumina paid us a $98.0 million termination fee (the “Reverse Termination Fee”), from which we paid our financial advisor associated fees of $6.0 million in April 2020. Pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we entered into a definitive agreement providing for, or consummated, a Change of Control Transaction, then we may have been required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. As indicated in ASC 450, Contingencies, a gain contingency usually is not recognized in the financial statements until the period in which all contingencies are resolved and the gain is realizable. As such, we deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency lapsed. On October 1, 2020, the contingency clauses lapsed and we recorded the $98.0 million as a part of other income in the fourth quarter of 2020.
CY2019Q4 pacb Proceeds From Contract Termination
ProceedsFromContractTermination
18000000.0
CY2020Q1 pacb Proceeds From Contract Termination
ProceedsFromContractTermination
34000000.0
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
34000000.0
CY2020Q1 pacb Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place
ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace
52000000.0
pacb Merger Agreement Period In Which Company Must Repay Continuation Advances If Change Of Control Transaction Is Entered Into With Third Party
MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty
P2Y
pacb Merger Agreement Continuation Advances Repayable Minimum Company Must Raise In Equity Or Debt Financing In Single Transaction
MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction
100000000
CY2021Q1 pacb Repayments Of Contract Termination
RepaymentsOfContractTermination
52000000.0
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-52000000.0
CY2020Q1 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
98000000.0
CY2020Q2 pacb Payments For Advisor Fees
PaymentsForAdvisorFees
6000000.0
CY2020Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000000.0
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements, which include the accounts of Pacific Biosciences and the accounts of our wholly-owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December 31, 2020 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive income (loss), and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020.
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, management evaluates its significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, and the valuations related to our convertible senior notes. Actual results could differ materially from these estimates.
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
425388000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
81611000
CY2021Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
654502000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
237203000
CY2021Q3 pacb Short Term Restricted Cash Fair Value Disclosure
ShortTermRestrictedCashFairValueDisclosure
500000
CY2020Q4 pacb Short Term Restricted Cash Fair Value Disclosure
ShortTermRestrictedCashFairValueDisclosure
836000
CY2021Q3 pacb Long Term Restricted Cash Fair Value Disclosure
LongTermRestrictedCashFairValueDisclosure
4560000
CY2020Q4 pacb Long Term Restricted Cash Fair Value Disclosure
LongTermRestrictedCashFairValueDisclosure
3500000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1084950000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
323150000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
168574000
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
168574000
CY2021Q1 pacb Repayments Of Contract Termination
RepaymentsOfContractTermination
52000000.0
CY2021Q3 us-gaap Profit Loss
ProfitLoss
16542000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-23708000
us-gaap Profit Loss
ProfitLoss
-111894000
us-gaap Profit Loss
ProfitLoss
-45532000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
202194000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166862000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
198545000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158195000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
202194000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166862000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
198545000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158195000
CY2021Q3 pacb Weighted Average Number Of Stock Options
WeightedAverageNumberOfStockOptions
7754000
CY2021Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
3598000
CY2021Q3 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
1581000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215127000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166862000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
198545000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158195000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
310875000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration and Other Risks For the three and nine months ended September 30, 2021, Gene Company Limited accounted for approximately 17% and 15%, respectively, of our total revenue during the period with no other customer exceeding 10% during those periods. For the three and nine months ended September 30, 2020, Gene Company Limited accounted for approximately 18% and 14%, respectively, of our total revenue with no other customer exceeding 10% during those periods. Gene Company Limited is our primary distributor in China.
CY2021Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1079862000
CY2021Q3 pacb Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
91000
CY2021Q3 pacb Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
63000
CY2021Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1079890000
CY2020Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
318729000
CY2020Q4 pacb Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
106000
CY2020Q4 pacb Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
21000
CY2020Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
318814000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
404995000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
152000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
715870000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
500000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
800000
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5511000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3531000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
8762000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6651000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4003000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4048000
CY2021Q3 us-gaap Inventory Net
InventoryNet
18276000
CY2020Q4 us-gaap Inventory Net
InventoryNet
14230000
pacb Annual Decrease In Long Term Restricted Cash
AnnualDecreaseInLongTermRestrictedCash
500000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3500000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
227000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
913000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
838000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
733000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
733000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
7762000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11206000
CY2021Q3 us-gaap Goodwill
Goodwill
411533000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18400000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7400000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
900000000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4085000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
895915000
CY2021Q2 pacb Contractual Interest Expense
ContractualInterestExpense
3375000
pacb Contractual Interest Expense
ContractualInterestExpense
8438000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
379000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3527000
us-gaap Interest Expense Debt
InterestExpenseDebt
8817000
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
886500000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
NOTE 9. COMMITMENTS AND CONTINGENCIES LeasesWe record an operating lease right-of-use assets and liabilities on our Condensed Consolidated Balance Sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our Condensed Consolidated Balance Sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. The following table presents information as to the amount and timing of cash flows arising from our operating leases as of September 30, 2021: Maturity of Lease LiabilitiesAmount Years ending December 31,(in thousands)Remainder of 2021$ 2,7142022 11,0302023 11,1632024 11,4012025 11,689Thereafter 21,941Total undiscounted operating lease payments 69,938Less: imputed interest (12,856)Present value of operating lease liabilities $ 57,082 Balance Sheet Classification Operating lease liabilities, current$ 7,128Operating lease liabilities, non-current 49,954Total operating lease liabilities$ 57,082We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted average discount rate used to measure our operating lease liabilities was 6.8%. The weighted average remaining lease term for our operating leases as of September 30, 2021 was 6.0 years. Cash FlowsCash paid for amounts included in the present value of operating lease liabilities was $1.8 million and $5.5 million, respectively, for the three and nine months ended September 30, 2021 and included in operating cash flow. Operating Lease CostsOperating lease costs were $1.6 million and $4.7 million, respectively, for the three and nine months ended September 30 of both 2021 and 2020. Contingencies We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.Legal U.S. District Court Proceedings On March 15, 2017, we filed a complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-275) (the “275 Action”). The complaint is based on our U.S. Patent No. 9,546,400 (the “’400 Patent”) which covers novel methods for nanopore sequencing of nucleic acid molecules using the signals from multiple monomeric units. We are seeking remedies including injunctive relief, damages and costs. On August 23, 2018, we filed an amended complaint, adding allegations of willful infringement and adding ONT Ltd. as a defendant in the 275 Action, which was granted on August 15, 2019.On September 25, 2017, we filed a second complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-1353) (the “1353 Action”). The complaint is based on our U.S. Patent No. 9,678,056 (the “’056 Patent”) and U.S. Patent No. 9,738,929. We are seeking remedies including injunctive relief, damages and costs. On March 28, 2018, we added a claim for infringement of our U.S. Patent No. 9,772,323 (the “’323 Patent”). On August 23, 2018 we filed an amended complaint, adding allegations of willful infringement and adding ONT Ltd. as a defendant in the 1353 Action, which was granted on August 15, 2019. A trial for the U.S. District Court matters was held from March 9 through March 18, 2020. The jury determined that ONT Inc. and ONT Ltd. infringed the ‘056 Patent, the ‘400 Patent, and the ‘323 Patent, but the jury declined to find these patents valid based on enablement and, in the case of the ’056 Patent, written description and indefiniteness. The jury declined to find valid or infringed U.S. Patent No. 9,738,929. Our appeal of the decision to the U.S. Court of Appeals for the Federal Circuit was denied on May 11, 2021.Unrelated to the preceding matters, on September 26, 2019, Personal Genomics of Taiwan, Inc. (“PGI”) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the “PGI District Court matter”). The matter from this complaint is based on PGI’s U.S. Patent No. 7,767,441 (the “‘441 Patent”). We plan to vigorously defend in this matter. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the ‘441 Patent. On June 22, 2020, we filed a petition requesting institution of an inter-partes review (IPR) to the Patent Trial and Appeals Board (the “Board”) at the United States Patent Office requesting the Board to find a set of claims in the ‘441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the ‘441 Patent invalid. The two petitions (the “PacBio IPR Petitions”) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions are instituted on all grounds presented.On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties. With the institution of the PacBio IPR Petitions described above, pursuant to the joint stipulation, the matter is now stayed pending a final written decision on the IPRs.Proceedings in ChinaOn May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People’s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the “CN321 Patent”), which is related to the ‘441 Patent. We were served on January 20, 2021 and plan to vigorously defend in this matter. On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. We have filed a petition with the Wuhan Intermediate People’s court requesting dismissal of the infringement action, which we anticipate will be granted. Other ProceedingsFrom time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.IndemnificationPursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of September 30, 2021.
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2714000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11030000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
11163000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
11401000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11689000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
21941000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
69938000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12856000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
57082000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7128000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49954000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
57082000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
1800000
us-gaap Payments For Rent
PaymentsForRent
5500000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000
us-gaap Operating Lease Cost
OperatingLeaseCost
4700000
us-gaap Operating Lease Cost
OperatingLeaseCost
4700000
CY2021Q3 pacb Additional Liability Associated With Indemnification Obligations
AdditionalLiabilityAssociatedWithIndemnificationObligations
0
CY2020Q1 pacb Share Based Compensation Arrangements By Share Based Payment Awards Number Of Active Plans
ShareBasedCompensationArrangementsByShareBasedPaymentAwardsNumberOfActivePlans
3
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35820000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4992000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61790000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12258000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.97
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.82
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.67
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.71
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34887000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19082000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94494000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51757000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34887000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19082000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94494000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51757000

Files In Submission

Name View Source Status
0001299130-21-000216-index-headers.html Edgar Link pending
0001299130-21-000216-index.html Edgar Link pending
0001299130-21-000216.txt Edgar Link pending
0001299130-21-000216-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pacb-20210930.xsd Edgar Link pending
pacb-20210930x10q.htm Edgar Link pending
pacb-20210930x10q_htm.xml Edgar Link completed
pacb-20210930xex10_4.htm Edgar Link pending
pacb-20210930xex31_1.htm Edgar Link pending
pacb-20210930xex31_2.htm Edgar Link pending
pacb-20210930xex32_1.htm Edgar Link pending
pacb-20210930xex32_2.htm Edgar Link pending
pacb-20210930_cal.xml Edgar Link unprocessable
pacb-20210930_def.xml Edgar Link unprocessable
pacb-20210930_lab.xml Edgar Link unprocessable
pacb-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending